Bioenvision shareholders shun Genzyme takeover bid

In a rare example of investor solidarity, the shareholders in control of Bioenvision stock effectively blocked a proposed $350 million takeover by Genzyme. Only 26 percent of shares were tendered by the deadline Sunday night, far fewer than the majority Genzyme needed to complete the sale. Genzyme, an aggressive player in the M&A game, said it would extend its deadline to July 10 and would be satisfied with a large stake in the company, if it comes to that. Genzyme says there's no talk of hiking the bid.

- check out the report from The Boston Globe

Related Articles:
Bioenvision investor balks at buyout agreement. Report
Genzyme snares cancer therapy in $345M buyout. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.